Literature DB >> 22985352

Inhaled pyrazinamide proliposome for targeting alveolar macrophages.

Wipaporn Rojanarat1, Titpawan Nakpheng, Ekawat Thawithong, Niracha Yanyium, Teerapol Srichana.   

Abstract

OBJECTIVE: In this study, pyrazinamide (PZA)-proliposome in a dry powder aerosol form was developed for delivering drugs to alveolar macrophages (AMs) infected with mycobacteria.
MATERIALS AND METHODS: PZA-proliposomes consisting of pyrazinamide, soybean phosphatidylcholine, cholesterol and porous mannitol were prepared by a spray drying method. The PZA-proliposome physicochemical properties were determined using a cascade impactor, X-ray diffraction, differential scanning calorimetry and infrared spectroscopy. The toxicity of proliposomes to respiratory-associated cell lines (Calu-3, A549 and NR8383) and its potential to provoke immunological responses from AMs were determined. In vivo repeated dose toxicity in rats was evaluated. RESULTS AND DISCUSSION: PZA-proliposomes were successfully prepared. For the aerosolization properties of PZA-proliposomes at 60 l/min, the powders showed mass median aerodynamic diameters of 4.26-4.39 µm, with fine particle fractions (aerosolized particles less than 4.4 µm) of 20-30%. Encapsulation of PZA was 26-45%. PZA-proliposomes were less toxic to respiratory-associated cells, and did not activate AMs to produce inflammatory mediators, including interleukin-1β, tumor necrosis factor-α, and nitric oxide, at a toxic level. Renal and liver toxicity in rats were not observed.
CONCLUSIONS: We suggest that PZA-proliposomes are potential candidates for pulmonary tuberculosis treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22985352     DOI: 10.3109/10717544.2012.721144

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  7 in total

Review 1.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

Review 2.  MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases.

Authors:  Kamal Dua; Nicole G Hansbro; Paul S Foster; Philip M Hansbro
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

3.  Carrier Effect in Development of Rifampin Loaded Proliposome for Pulmonary Delivery: A Quality by Design Study.

Authors:  Elahehnaz Parhizkar; Delaram Sadeghinia; Hamed Hamishehkar; Shadi Yaqoubi; Ali Nokhodchi; Shohreh Alipour
Journal:  Adv Pharm Bull       Date:  2021-05-18

Review 4.  Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.

Authors:  Caleb F Anderson; Maria E Grimmett; Christopher J Domalewski; Honggang Cui
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-10-10

Review 5.  Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis.

Authors:  Amarjitsing Rajput; Satish Mandlik; Varsha Pokharkar
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 6.  The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.

Authors:  Roberto Nisini; Noemi Poerio; Sabrina Mariotti; Federica De Santis; Maurizio Fraziano
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

Review 7.  Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications.

Authors:  Ngoc Thuy Trang Le; Van Du Cao; Thi Nhu Quynh Nguyen; Thi Thu Hong Le; Thach Thao Tran; Thai Thanh Hoang Thi
Journal:  Int J Mol Sci       Date:  2019-09-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.